Physician profile
James D Murphy
NPI 1073584256
$18,355.30
in general payments reported to CMS, 2019-2025
26 companies · $10K in 2025
The $10K reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,310 · 2020: $722 · 2021: $1,296 · 2022: $1,537 · 2023: $1,292 · 2024: $1,139 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,325 · Food and Beverage: $4,130 · Education: $35.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,325.00 |
| Food and Beverage | $4,129.78 |
| Education | $35.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $9,992.62 | 2019-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $1,653.00 | 2019-2025 | |
| Pfizer INC. | $766.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $705.00 | 2019-2024 | Xarelto |
| United Therapeutics Corporation | $557.51 | 2019-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $544.76 | 2019-2025 | Accolade Sr, Resonate El Icd Vr |
| Amgen INC. | $526.79 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $522.20 | 2019-2025 | Camzyos |
| Abbott Laboratories | $496.20 | 2021-2025 | Cardiomems, Gallant, Ensite |
| Bayer Healthcare Pharmaceuticals INC. | $419.98 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $416.83 | 2022-2025 | Winrevair, Verquvo |
| Astrazeneca Pharmaceuticals Lp | $281.41 | 2019-2024 | Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.84 | 2019-2021 | |
| Novo Nordisk INC | $269.23 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $226.89 | 2019-2025 | Evkeeza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $148.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $136.95 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $111.92 | 2019 | |
| Gilead Sciences, INC. | $108.00 | 2019 | |
| Esperion Therapeutics, INC. | $82.49 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $36.38 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.40 | 2023 | Inpefa |
| Procyrion, INC. | $21.09 | 2022 | |
| Siemens Medical Solutions USA, INC. | $17.20 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.76 | 2024 | Tryvio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.